Oluwarotimi Nettey
Urogynecology and Reconstructive Pelvic Surgery · Houston, TXNPI 1467878314
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medtronic at 59.4% of the total. Reporting peaked in 2021 at $10,615 and has fallen 98.3% since, to $176 in 2025.
Across 77 payments — averaging $244.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Axonics, Inc.$3K
- Boston Scientific$3K
- Intuitive Surgical$1K
- Travere Therapeutics, Inc.$562
- AbbVie$148
- plus $202 from 3 others
What the payments were for
- Grants$10,00053%
- Travel & lodging$2,26112%
- Food & beverage$5,53929%
- Education$1,0005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $11,169 |
| Axonics, Inc. | 24 | $3,127 |
| Boston Scientific | 28 | $2,535 |
| Intuitive Surgical | 3 | $1,058 |
| Travere Therapeutics, Inc. | 4 | $562 |
| AbbVie | 1 | $148 |
| Sanofi | 1 | $127 |
| Dornier Medtech America, Inc | 1 | $52 |
| 180 Medical, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$10,832
- Axonics$2,287
- Bulkamid$1,773
- DAVINCI XI$1,000
- (815) Thiola$562
- rezum Generator$321
- GENERAL MALE SUI$151
- BOTOX$148
- AdVance XP$116
- LithoVue$114
- GENERAL KIDNEY STONE DISEASE$113
- AMS$112
- Solyx SIS System$108
- Axonics r-SNM System$104
How this compares
$18,800 in reported general payments places this provider in the 85th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 57 | $38,752 |
| MyrbetriqMirabegron | 37 | $21,213 |
| Estradiol | 66 | $5,292 |
| YuvafemEstradiol | 14 | $2,915 |
| Trospium Chloride | 13 | $1,377 |
| Solifenacin Succinate | 12 | $461 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $39 |
| Tramadol Hcl | 16 | $18 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Houston
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Linh DoHouston$11K
- Christine PanHouston$11K
- Apurva PancholyHouston$10K
- Danielle AntoshHouston$8K
- Khadijah EidHouston$8K
- Emily RutledgeHouston$5K
- Sarah RozyckiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.